ArticleJournal of translational medicine2025
Lysyl oxidase promotes seminal vesicle atrophy and fibrosis in type-2 diabetes mellitus through TGF-β1 signaling.
Article in Journal of translational medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Levocarnitine attenuates diabetic seminal vesicle fibrosis in association with improved lipid metabolism and reduced ER stress.iScience · 2026Article
- Platelet-Rich Plasma (PRP) bidirectionally modulates scar formation via the Piezo1-YAP/TAZ axis: a novel mechanotransduction hypothesis.Frontiers in cell and developmental biology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Type-2 diabetes mellitus (T2DM) is a complex metabolic disorder that adversely affects various physiological systems, particularly male reproductive health. Research indicates that T2DM increases the risk of retrograde ejaculation, impairing sexual function and fertility. Dysregulation of lysyl oxidase (LOX) has been linked to diabetes-related complications in the male reproductive system. However, its role in seminal vesicle remains unclear. This study investigates LOX's involvement in diabetes-related seminal vesicle pathology using human and mouse models. We assessed LOX expression in the seminal vesicles of men with T2DM and created a T2DM mouse model to observe changes. Our findings revealed elevated LOX expression in the seminal vesicles of T2DM men, accompanied by epithelial atrophy and fibrosis. Similarly, T2DM mice displayed significant atrophy and fibrosis of the seminal vesicles, correlated with increased LOX levels. Treatment with the LOX inhibitor, β-aminopropionitrile (BANP), significantly improved extracellular matrix remodeling and normalized the architecture of the seminal vesicles. Besides, LOX inhibition led to a significant reduction in T lymphocyte infiltration and apoptosis in the seminal vesicle epithelium of T2DM mice.These results highlight LOX's critical role in seminal vesicle fibrosis associated with T2DM. Targeting LOX may provide a promising therapeutic strategy to alleviate reproductive complications and preserve reproductive health in men with T2DM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.